Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8479695 | 0.98 | SIGMAR1 (0.58) | SIGMAR1DRD2DRD4DRD3CHRM2 | |
| SCHEMBL2959946 | 0.91 | SIGMAR1 (0.57) | SIGMAR1DRD2CHRM3CYP2C19ALDH1A1 | |
| SCHEMBL1206639 | 0.91 | SIGMAR1 (0.69) | SIGMAR1DRD2DRD4DRD3SMN1; SMN2 | |
| SCHEMBL238565 | 0.86 | DRD2 (0.57) | SIGMAR1DRD2DRD4DRD3CHRM2 | |
| SCHEMBL3563415 | 0.86 | DRD2 (0.57) | SIGMAR1DRD2DRD4DRD3CHRM2 | |
| SCHEMBL2327650 | 0.86 | DRD2 (0.57) | SIGMAR1DRD2DRD4DRD3CHRM2 | |
| SCHEMBL6584141 | 0.84 | DRD2 (0.55) | DRD2DRD4DRD3CHRM2CHRM3 | |
| SCHEMBL4278988 | 0.84 | DRD2 (0.55) | DRD2DRD4DRD3CHRM2CHRM3 | |
| SCHEMBL2322360 | 0.84 | DRD2 (0.55) | DRD2DRD4DRD3CHRM2CHRM3 | |
| SCHEMBL2202545 | 0.82 | DRD4 (0.53) | DRD2DRD4DRD3CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1938291-B | Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV | 2011-11-16 | — | — | CN | disclosed |
| EP-2099761-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| WO-2008068272-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| EP-1737838-B1 | SUBSTITUTED 4-ALKYL- AND 4-ALKANOYL-PIPERIDINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-21 | — | — | EP | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| CN-1938291-A | Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-28 | — | — | CN | disclosed |
| US-5922717-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| WO-1996020173-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | SIGMAR1 188/4885DRD2 1354/4885DRD4 1086/4885 |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | NPSR1, VIP, OPRK1 | SIGMAR1 730/4885DRD2 441/4885DRD4 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.